These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17196049)

  • 1. Remission in first-episode psychosis: predictor variables and symptom improvement patterns.
    Emsley R; Oosthuizen PP; Kidd M; Koen L; Niehaus DJ; Turner HJ
    J Clin Psychiatry; 2006 Nov; 67(11):1707-12. PubMed ID: 17196049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.
    Yoshimura B; Sakamoto S; Sato K; Takaki M; Yamada N
    Early Interv Psychiatry; 2019 Jun; 13(3):589-597. PubMed ID: 29498481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.
    Perkins D; Lieberman J; Gu H; Tohen M; McEvoy J; Green A; Zipursky R; Strakowski S; Sharma T; Kahn R; Gur R; Tollefson G;
    Br J Psychiatry; 2004 Jul; 185():18-24. PubMed ID: 15231551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
    Emsley R; Rabinowitz J; Medori R;
    Schizophr Res; 2007 Jan; 89(1-3):129-39. PubMed ID: 17095194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
    Oosthuizen PP; Emsley RA; Maritz JS; Turner JA; Keyter N
    J Clin Psychiatry; 2003 Sep; 64(9):1075-80. PubMed ID: 14628983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
    Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
    J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
    Díaz I; Pelayo-Terán JM; Pérez-Iglesias R; Mata I; Tabarés-Seisdedos R; Suárez-Pinilla P; Vázquez-Barquero JL; Crespo-Facorro B
    Psychiatry Res; 2013 Apr; 206(2-3):181-7. PubMed ID: 23159063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
    Kane JM; Crandall DT; Marcus RN; Eudicone J; Pikalov A; Carson WH; Swyzen W
    Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
    Pelayo-Terán JM; Diaz FJ; Pérez-Iglesias R; Suárez-Pinilla P; Tabarés-Seisdedos R; de León J; Crespo-Facorro B
    Psychol Med; 2014 Jan; 44(1):37-50. PubMed ID: 23461899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of early stable symptomatic remission after an exacerbation of schizophrenia: the significance of symptoms, neuropsychological performance and cognitive biases.
    Andreou C; Roesch-Ely D; Veckenstedt R; Bohn F; Aghotor J; Köther U; Pfueller U; Moritz S
    Psychiatry Res; 2013 Dec; 210(3):729-34. PubMed ID: 23998362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An early improvement threshold to predict response and remission in first-episode schizophrenia.
    Schennach-Wolff R; Seemüller FH; Mayr A; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Häfner H; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Riedel M
    Br J Psychiatry; 2010 Jun; 196(6):460-6. PubMed ID: 20513856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
    Volavka J; Czobor P; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
    J Clin Psychiatry; 2011 Jul; 72(7):955-61. PubMed ID: 21824456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adolescent vs. adult onset of a first episode psychosis: Impact on remission of positive and negative symptoms.
    Veru F; Jordan G; Joober R; Malla A; Iyer S
    Schizophr Res; 2016 Jul; 174(1-3):183-188. PubMed ID: 27102425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
    Meltzer HY; Arvanitis L; Bauer D; Rein W;
    Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.